{"id":482827,"date":"2021-04-27T16:33:41","date_gmt":"2021-04-27T20:33:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/"},"modified":"2021-04-27T16:33:41","modified_gmt":"2021-04-27T20:33:41","slug":"codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/","title":{"rendered":"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting"},"content":{"rendered":"<h2>\n\u2013 engEx\u2122 Platform and in vitro and in vivo findings support utility across multiple therapeutic areas \u2013<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., April  27, 2021  (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the company will present data from its engEx\u2122 Platform at the 24<sup>th<\/sup> Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held virtually from May 11-14, 2021. Codiak scientists will present four abstracts detailing results from numerous preclinical studies evaluating the potential utility of engineered exosomes in multiple settings, including oncology, infectious disease, gene therapy and neurology.<\/p>\n<p align=\"left\">\u201cIn addition to our current clinical programs that are testing engineered exosome therapeutic candidates in immuno-oncology, we see broad opportunity for our platform to create novel, targeted therapeutic approaches in multiple disease areas,\u201d said Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak. \u201cThe data to be presented at ASGCT highlights the power of the engEx platform to engineer specific features into exosomes for immune evasion, targeted cell tropism, and potent engagement of previously undruggable pathways, characteristics that serve as the foundation of a new class of medicines.\u201d<\/p>\n<p align=\"left\">\n        <strong>Poster Presentations &#8211; May 11, 2021; 8:00 a.m. \u2013 10:00 a.m. ET<\/strong>:<\/p>\n<p align=\"left\">\n        <strong>exoVACC\u2122:\u00a0A\u00a0Novel Exosome-Based Vaccine Platform That Induces Robust, Tunable Cellular and Humoral Immune Responses in Animal Models<\/strong><br \/>\n        <br \/>\n        <em>Abstract number:<\/em> 721<br \/><em>Session: <\/em>Immunological Aspects for Gene Therapy and Vaccines<\/p>\n<p align=\"justify\">\n        <strong>Optimization of AAV Loading Into Extracellular Vesicles as Method to Avoid Neutralizing Antibodies<\/strong><br \/>\n        <br \/>\n        <em>Abstract number:<\/em> 320<br \/><em>Session: <\/em>AAV Vectors \u2013 Virology and Vectorology<\/p>\n<p align=\"left\">\n        <strong>Engineered Exosomes Efficiently Deliver STAT6 Antisense Oligonucleotides to Tumor Associated Macrophages (TAMs) Resulting in Potent Local and Systemic Anti-Tumor Activity<\/strong><br \/>\n        <br \/>\n        <em>Abstract number:<\/em> 444<br \/><em>Session: <\/em>Oligonucleotide Therapeutics<\/p>\n<p align=\"left\">\n        <strong>Engineering Exosomes With Altered Cellular Tropism for Neuronal Cell Targeting<\/strong><br \/>\n        <br \/>\n        <em>Abstract number:<\/em> 808<br \/><em>Session: <\/em>Vector Product Engineering, Development or Manufacturing<\/p>\n<p align=\"left\">\n        <strong>About the engEx\u2122 Platform<\/strong><br \/>\n        <br \/>Codiak\u2019s proprietary engEx Platform is designed to enable the development of engineered exosome therapeutics for a wide spectrum of diseases and\u00a0to manufacture\u00a0them reproducibly and at scale to pharmaceutical standards. By leveraging the inherent biology, function and tolerability profile of exosomes, Codiak is developing engEx exosomes designed to carry and protect potent drug molecules, provide selective delivery and elicit the desired pharmacology at the desired tissue and cellular sites. Through its engEx Platform, Codiak seeks to direct tropism and distribution by engineering exosomes to carry on their surface specific targeting drug moieties, such as proteins, antibodies\/fragments, and peptides, individually or in combination. Codiak scientists have identified two exosomal proteins that serve as surface and luminal scaffolds. By engineering the exosome surface or lumen and optimizing the route of administration, Codiak aims to deliver engEx exosomes\u00a0to the desired cell and tissue to more selectively engage the drug target, potentially enhancing the therapeutic index by improving potency and reducing toxicity.<\/p>\n<p align=\"left\">\n        <strong>About Codiak BioSciences <\/strong><br \/>\n        <br \/>Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of exoIL-12 and exoASO-STAT6, including future development plans and regulatory filings and timing with respect thereto. Any forward-looking statements in this press release are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in Codiak\u2019s Annual Report on Form\u00a010-K\u00a0for the year ended December\u00a031, 2020, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiak\u2019s subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/377c5a33-78a1-4ff4-b922-2cb3aa6cdfb1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\nChristopher Taylor\r\nVP, Investor Relations and Corporate Communications\r\nT: 617-949-4220\r\nE: investor@codiakbio.com\r\n\r\nMedia Contact:\r\nLindy Devereux\r\nScient PR\r\nT: 646-515-5730\r\nE: media@codiakbio.com\u00a0<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 engEx\u2122 Platform and in vitro and in vivo findings support utility across multiple therapeutic areas \u2013 CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the company will present data from its engEx\u2122 Platform at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held virtually from May 11-14, 2021. Codiak scientists will present four abstracts detailing results from numerous preclinical studies evaluating the potential utility of engineered exosomes in multiple settings, including oncology, infectious disease, gene therapy and neurology. \u201cIn addition to our current clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-482827","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 engEx\u2122 Platform and in vitro and in vivo findings support utility across multiple therapeutic areas \u2013 CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the company will present data from its engEx\u2122 Platform at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held virtually from May 11-14, 2021. Codiak scientists will present four abstracts detailing results from numerous preclinical studies evaluating the potential utility of engineered exosomes in multiple settings, including oncology, infectious disease, gene therapy and neurology. \u201cIn addition to our current clinical &hellip; Continue reading &quot;Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T20:33:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting\",\"datePublished\":\"2021-04-27T20:33:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/\"},\"wordCount\":802,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/\",\"name\":\"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=\",\"datePublished\":\"2021-04-27T20:33:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk","og_description":"\u2013 engEx\u2122 Platform and in vitro and in vivo findings support utility across multiple therapeutic areas \u2013 CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) &#8212; Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the company will present data from its engEx\u2122 Platform at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held virtually from May 11-14, 2021. Codiak scientists will present four abstracts detailing results from numerous preclinical studies evaluating the potential utility of engineered exosomes in multiple settings, including oncology, infectious disease, gene therapy and neurology. \u201cIn addition to our current clinical &hellip; Continue reading \"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-27T20:33:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting","datePublished":"2021-04-27T20:33:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/"},"wordCount":802,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/","name":"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=","datePublished":"2021-04-27T20:33:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyNDcyMiM0MTQxNjI3IzIxNTcwMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codiak-to-present-preclinical-data-demonstrating-broad-potential-applications-for-engineered-exosomes-at-the-american-society-for-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=482827"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482827\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=482827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=482827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=482827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}